Next Generation Antibody Drug Global Market Report 2025

The next generation antibody drug market size has grown rapidly in recent years. It will grow from $14.26 billion in 2024 to $16.54 billion in 2025 at a compound annual growth rate (CAGR) of 16%. The growth during the historic period can be attributed to the increasing demand for targeted therapies, rising cancer prevalence, growing adoption of immuno-oncology therapies, heightened focus on autoimmune diseases, and expanding regulatory support.

The next generation antibody drug market size is expected to see rapid growth in the next few years. It will grow to $29.72 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period is expected to be driven by rising demand for personalized medicine, expanding drug pipelines, increasing healthcare awareness, more research collaborations, and a growing aging population. Major trends in the forecast period include advancements in antibody-drug conjugates, technological progress in bispecific antibodies, integration of next-generation sequencing, developments in protein engineering, and advancements in gene therapy integration.

The growing emphasis on personalized medicine is anticipated to drive the expansion of the next-generation antibody-drug market. Personalized medicine tailors healthcare and treatment approaches to individual patients, considering their genetic, environmental, and lifestyle factors to provide more effective and targeted therapies. This shift toward personalized medicine is fueled by advancements in genomic sequencing, which allow for more accurate diagnoses and customized treatment plans. Next-generation antibody drugs support this trend by enabling the development of therapies tailored to a patient's unique genetic makeup and disease characteristics, enhancing efficacy and reducing side effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization promoting personalized medicine, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases, up from 6 in 2022. Thus, the growing emphasis on personalized medicine is driving the next-generation antibody drug market.

Companies in the next-generation antibody drug market are focusing on developing innovative solutions, such as antibody-drug conjugates (ADCs), to improve targeted cancer therapies, enhance treatment efficacy, and minimize systemic toxicity. ADCs combine a monoclonal antibody with a cytotoxic drug via a linker, allowing the drug to specifically target tumor cells while sparing healthy tissue. For instance, in January 2024, BioNTech SE, a Germany-based biotechnology firm, partnered with Duality Biologics (Suzhou) Co. Ltd., a Chinese pharmaceutical company, to receive a Fast Track designation from the U.S. FDA for their ADC candidate, BNT325/DB-1305, intended to treat platinum-resistant ovarian cancer. This drug utilizes DualityBio’s DITAC (Duality Immune Toxin Antibody Conjugates) platform, which pairs a highly potent cytotoxic payload with a monoclonal antibody, ensuring precise delivery to cancer cells. The ability of BNT325/DB-1305 to selectively target cancer cells while minimizing harm to healthy tissue is a key advantage in enhancing treatment outcomes and reducing side effects.

In March 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, acquired Ambrx Biopharma for an undisclosed sum. Through this acquisition, Johnson & Johnson aims to enhance its oncology portfolio by developing advanced, targeted antibody-drug conjugates that improve outcomes and minimize side effects for patients with hard-to-treat cancers. Ambrx Biopharma is dedicated to advancing the development of next-generation antibody-drug conjugates.

Major players in the next generation antibody drug market are Actinium Pharmaceuticals Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited.

North America was the largest region in the next generation antibody drug market in 2024. The regions covered in next generation antibody drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next generation antibody drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next generation antibody drug market consists of sales of engineered monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and related biologic therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.